Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96PN8
UPID:
TSSK3_HUMAN
Alternative names:
Serine/threonine-protein kinase 22C
Alternative UPACC:
Q96PN8; Q5TEE5
Background:
Testis-specific serine/threonine-protein kinase 3, alternatively known as Serine/threonine-protein kinase 22C, plays a crucial role in male germ cell development and mature sperm function. Its involvement in signaling pathways underscores its importance in reproductive biology.
Therapeutic significance:
Understanding the role of Testis-specific serine/threonine-protein kinase 3 could open doors to potential therapeutic strategies. Its pivotal role in sperm function and male fertility highlights its potential as a target for addressing reproductive health issues.